Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Cancer Chemother Pharmacol · 2019 · PMC6768912 · PMID 31444619

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The proportion of patients reduced to 43.8% at week 4 and showed an increasing trend in later weeks (51.0% at week 6, 54.9% at week 10 and 68.3% at week 16).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.